AU2006281415B2 - Pancreatin micropellet cores suitable for enteric coating - Google Patents

Pancreatin micropellet cores suitable for enteric coating Download PDF

Info

Publication number
AU2006281415B2
AU2006281415B2 AU2006281415A AU2006281415A AU2006281415B2 AU 2006281415 B2 AU2006281415 B2 AU 2006281415B2 AU 2006281415 A AU2006281415 A AU 2006281415A AU 2006281415 A AU2006281415 A AU 2006281415A AU 2006281415 B2 AU2006281415 B2 AU 2006281415B2
Authority
AU
Australia
Prior art keywords
pancreatin
pancreatin micropellet
cores
micropellet
micropellet cores
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006281415A
Other languages
English (en)
Other versions
AU2006281415A1 (en
Inventor
Claus-Juergen Koelln
Jens Onken
Guido Ruesing
Frithjof Sczesny
George Shlieout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories GmbH
Original Assignee
Abbott Laboratories GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37401623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006281415(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories GmbH filed Critical Abbott Laboratories GmbH
Publication of AU2006281415A1 publication Critical patent/AU2006281415A1/en
Application granted granted Critical
Publication of AU2006281415B2 publication Critical patent/AU2006281415B2/en
Assigned to ABBOTT PRODUCTS GMBH reassignment ABBOTT PRODUCTS GMBH Request to Amend Deed and Register Assignors: SOLVAY PHARMACEUTICALS GMBH
Assigned to ABBOTT LABORATORIES GMBH reassignment ABBOTT LABORATORIES GMBH Request for Assignment Assignors: ABBOTT PRODUCTS GMBH
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Finger-Pressure Massage (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2006281415A 2005-08-15 2006-08-15 Pancreatin micropellet cores suitable for enteric coating Active AU2006281415B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70852605P 2005-08-15 2005-08-15
EP05107474.8 2005-08-15
US60/708,526 2005-08-15
EP05107474 2005-08-15
PCT/EP2006/065313 WO2007020260A2 (en) 2005-08-15 2006-08-15 Pancreatin micropellet cores suitable for enteric coating

Publications (2)

Publication Number Publication Date
AU2006281415A1 AU2006281415A1 (en) 2007-02-22
AU2006281415B2 true AU2006281415B2 (en) 2012-01-19

Family

ID=37401623

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006281415A Active AU2006281415B2 (en) 2005-08-15 2006-08-15 Pancreatin micropellet cores suitable for enteric coating

Country Status (15)

Country Link
EP (1) EP1931317B1 (https=)
JP (1) JP5284092B2 (https=)
KR (1) KR101302841B1 (https=)
AT (1) ATE418329T1 (https=)
AU (1) AU2006281415B2 (https=)
CA (1) CA2619477C (https=)
DE (1) DE602006004471D1 (https=)
ES (1) ES2320174T3 (https=)
IL (1) IL189457A (https=)
MX (1) MX2008001557A (https=)
NO (1) NO20081379L (https=)
PL (1) PL1931317T3 (https=)
PT (1) PT1931317E (https=)
RU (1) RU2408364C2 (https=)
WO (1) WO2007020260A2 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
CA2560613C (en) 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
HUE031042T2 (en) 2005-07-29 2017-06-28 Abbott Laboratories Gmbh Methods for producing pancreatin powder with low viral content
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US8246950B2 (en) 2007-02-20 2012-08-21 Aptalis Pharma Limited Stable digestive enzyme compositions
JP2011508755A (ja) * 2008-01-03 2011-03-17 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 精製微生物リパーゼの顆粒を有する医薬組成物ならびに消化器疾患を予防又は治療する方法
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
EP2318035B1 (en) 2008-07-01 2019-06-12 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA2747611C (en) 2009-01-06 2019-09-17 Curemark Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
WO2010080835A1 (en) 2009-01-06 2010-07-15 Curemark Llc Compositions and methods for the treatment or the prevention oral infections by e. coli
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP2295039B2 (de) 2009-08-28 2022-10-26 Nordmark Pharma GmbH Verfahren zur Herstellung von Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und hiernach hergestellte Pankreatin-Pellets
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
UA111726C2 (uk) 2010-10-01 2016-06-10 Апталіс Фарма Лімітед Препарат панкреліпази низької сили з кишковорозчинним покриттям
DE202011000728U1 (de) 2011-03-30 2011-06-09 Nordmark Arzneimittel GmbH & Co. KG, 25436 Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets
EP2489349B1 (de) 2011-02-17 2014-05-28 Nordmark Arzneimittel GmbH & Co.KG Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und Verfahren zu deren Herstellung
JP5976100B2 (ja) 2011-04-21 2016-08-23 キュアマーク リミテッド ライアビリティ カンパニー 神経精神障害の処置のための化合物
CA2843556A1 (en) 2011-08-08 2013-02-14 Aptalis Pharma Ltd. Method for dissolution testing of solid compositions containing digestive enzymes
US10350278B2 (en) * 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
MX2016001593A (es) 2013-08-09 2016-09-29 Allergan Pharmaceuticals Int Ltd Composicion de enzima digestiva adecuada para administracion enterica.
JP2017519490A (ja) 2014-06-19 2017-07-20 アプタリス ファルマ リミテッド 膵臓抽出物からのウイルス汚染の除去方法
WO2016071434A1 (en) 2014-11-05 2016-05-12 Abbott Laboratories Gmbh Processes for producing compositions with improved safety profile comprising pancreatin and compositions suitable for pharmaceutical use
DE102017104482A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutische Zusammensetzung umfassend Pankreatin und einen lipasehaltigen Überzug
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
RU2706003C1 (ru) * 2019-09-09 2019-11-13 Акционерное общество "АВВА РУС" Микрогранулы, содержащие панкреатин
MX2022014395A (es) * 2020-06-10 2022-12-02 Kusum Healthcare Pvt Ltd Composicion farmaceutica de pancreatina.
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
KR102950325B1 (ko) 2024-01-26 2026-04-08 황준영 판크레아틴 함유 속방성 장용코팅 정제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079125A (en) * 1975-06-10 1978-03-14 Johnson & Johnson Preparation of enteric coated digestive enzyme compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227385A1 (de) * 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
KR19990072826A (ko) * 1998-02-26 1999-09-27 우재영 판크레아틴장용코팅과립의제조방법
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
ATE242003T1 (de) * 1999-03-17 2003-06-15 Solvay Pharm Gmbh Enzyme zur behandlung von diabetes mellitus typ i
IT1319655B1 (it) * 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079125A (en) * 1975-06-10 1978-03-14 Johnson & Johnson Preparation of enteric coated digestive enzyme compositions

Also Published As

Publication number Publication date
KR101302841B1 (ko) 2013-09-02
WO2007020260A3 (en) 2007-05-10
MX2008001557A (es) 2008-02-15
NO20081379L (no) 2008-05-14
PL1931317T3 (pl) 2009-06-30
EP1931317B1 (en) 2008-12-24
IL189457A (en) 2014-05-28
RU2008109651A (ru) 2009-09-27
JP2009504710A (ja) 2009-02-05
ES2320174T3 (es) 2009-05-19
CA2619477C (en) 2015-05-26
JP5284092B2 (ja) 2013-09-11
IL189457A0 (en) 2008-06-05
KR20080034516A (ko) 2008-04-21
HK1119559A1 (en) 2009-03-13
EP1931317A2 (en) 2008-06-18
CA2619477A1 (en) 2007-02-22
PT1931317E (pt) 2009-02-02
DE602006004471D1 (de) 2009-02-05
RU2408364C2 (ru) 2011-01-10
AU2006281415A1 (en) 2007-02-22
ATE418329T1 (de) 2009-01-15
WO2007020260A2 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
AU2006281415B2 (en) Pancreatin micropellet cores suitable for enteric coating
US20240148660A1 (en) Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) Delayed release pancreatin compositions
AU2006281414B2 (en) Controlled release pharmaceutical compositions for acid labile drugs
NZ565959A (en) Pancreatin micropellet cores suitable for enteric coating
KR101344546B1 (ko) 산 불안정성 약제를 위한 조절방출 약제학적 조성물
HK1119559B (en) Pancreatin micropellet cores suitable for enteric coating
HK1121037B (en) Controlled release pharmaceutical compositions for acid labile drugs

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE NAME FROM SOLVAY PHARMACEUTICALS GMBH TO ABBOTT PRODUCTS GMBH .

PC Assignment registered

Owner name: ABBOTT LABORATORIES GMBH

Free format text: FORMER OWNER WAS: ABBOTT PRODUCTS GMBH